Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study
Journal
BMC medicine
Journal Volume
21
Journal Issue
1
Date Issued
2023-10-20
Author(s)
Abstract
GT90001 (also known as PF-03446962) is an anti-ALK-1 monoclonal antibody and has shown activity in hepatocellular carcinoma (HCC). This phase 1b/2 study was designed to determine the recommended phase 2 dose (RP2D) of GT90001 plus nivolumab, and assess the safety and anti-tumor activity in patients with advanced HCC.
Subjects
Anti-angiogenic therapy; GT90001; Hepatocellular carcinoma; Immunotherapy; Nivolumab; PF-03446962
SDGs
Type
journal article